Pancreatic cancer is a malignant tumor of the digestive system. In the early stages, most pancreatic cancer patients generally have normal routine blood test indicators and show no abnormalities. This is because the early lesions are localized, without invasion or metastasis, and therefore have minimal impact on the overall body, not causing abnormalities in routine blood test indicators. As the disease progresses, patients in the middle and late stages of pancreatic cancer often exhibit abnormalities in routine blood test indicators, mainly manifested as abnormalities in hemoglobin levels. Patients experience mild, moderate, or severe anemia. Some patients may also have metastasis to the bone marrow, liver, spleen, etc. Clinically, there can also be a decrease in white blood cells and platelets. Due to the impact of pancreatic cancer lesions on liver function, there can also be abnormalities in coagulation function.